Skip to content

Efficacy and safety of intra-arterial thrombolysis in acute ischemic stroke patients without large or medium vessel occlusion stroke a multi-center, prospective, randomized, blind-endpoint trial

Efficacy and safety of intra-arterial thrombolysis in acute ischemic stroke patients without large or medium vessel occlusion stroke a multi-center, prospective, randomized, blind-endpoint trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400081660
Enrollment
Unknown
Registered
2024-03-07
Start date
2024-03-07
Completion date
Unknown
Last updated
2024-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute ischemic stroke

Interventions

Intra-arterial urokinase thrombolysis plus standard treatment group:Intra-arterial urokinase thrombolysis plus standard treatment

Sponsors

The Second Affiliated Hospital of the Army Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1)Age = 18 years old; 2)Within 24 hours of stroke onset; 3)Without visible large or medium vessel occlusion on DSA/CTA/MRA examination. 4)National Institutes of Health Stroke Scale (NIHSS) score = 6 points; 5)Written informed consent signed by the patient or family members.

Exclusion criteria

Exclusion criteria: 1)Confirmed intracranial hemorrhage by computed tomography (CT) or magnetic resonance imaging (MRI); 2)Pre-stroke mRS score = 2; 3)Digital subtraction angiography suggests vascular rupture, dissection, extravasation of contrast agent or other complication; 4)Alberta Stroke Program Early CT Score (ASPECTS) 1.7; 9)Blood glucose 22.2mmol/L (400mg/dl), platelets 220µmol/L(2.5mg/dl)); 12)Intracranial aneurysm, or arteriovenous malformation; 13)Brain tumor(s) with mass effect; 14)Any disease that leads to an expected lifespan of less than 6 months; 15)Unable to complete follow-up as expected; 16)Large- or medium-sized vessel occlusion found on DSA/CTA/MRA examination; 17)Currently participating in other clinical trial; 18)Patients received Intravenous Thrombolysis

Design outcomes

Primary

MeasureTime frame
Modified Rankin Scale score 0-1;Symptomatic intracranial hemorrhage;Death;

Secondary

MeasureTime frame
Global outcome analysis;Modified Rankin Scale score of 0-2;EQ-5D scale score;any intracranial hemorrhage;NIHSS score at 5 to 7 days;

Countries

China

Contacts

Public ContactWenjie Zi

The Second Affiliated Hospital of the Army Medical University

ziwenjie1981@163.com+86 185 2303 3816

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026